Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
AXSM Analyst Ratings
Strong Buy
16 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AXSM Stock 12 Month Forecast
Average Price Target
$173.25
▲(36.35% Upside)
| Highest Price Target$200.00 | Average Price Target$173.25 | Lowest Price Target$148.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Morgan Stanley
$191→$194
Buy
52.68%
Upside
Reiterated
10/20/25
Axsome Therapeutics: Strategic Growth and Promising Commercial Progress Drive Buy RatingWe estimate Auvelity 3Q25 revenues of $129mn in MDD. Recall Axsome completed a sales force expansion for Auvelity in 1Q25, adding 40 reps to the sales force (bringing the total to 300 representatives). Mgt. has noted that TRx growth is expected throughout the remainder of the year, given the sales force expansion. 3Q25 IQVIA scripts show 8% Q/Q growth. Based on our analysis of IQVIA TRx data, estimated IQVIA script capture ratio, Auvelity GTN and pricing, we arrive at an Auvelity 3Q25 total MDD sales estimate of $129mn, which is in-line with Visible Alpha consensus estimates.
UBS
$144→$163
Buy
28.29%
Upside
Reiterated
10/16/25
RBC Capital
―
Buy
―
Reiterated
10/08/25
Leerink Partners
―
Buy
―
Reiterated
10/07/25
B. Riley Securities
$179
Buy
40.88%
Upside
Initiated
10/01/25
William Blair
―
Buy
―
Reiterated
09/19/25
Axsome Therapeutics: Strong Growth Trajectory and Financial Outlook Justify Buy RatingWe hosted for investor calls in Europe. We discuss key takeaways from our meetings in the full note. Heading into the sNDA submission for Auvelity in Alzheimer’s disease agitation (AD-A) expected this quarter, Axsome is an emerging sustainable biotech growth story, in our view. Auvelity in major depressive disorder is annualizing more than $475 million in revenue after only 11 quarters of launch, and the company is diversifying through AXS-12 (NDA expected fourth quarter 2025).
Piper Sandler
$148
Buy
16.48%
Upside
Reiterated
09/17/25
Cantor Fitzgerald
$153
Buy
20.42%
Upside
Reiterated
09/15/25
Wells Fargo
$163
Buy
28.29%
Upside
Initiated
09/03/25
H.C. Wainwright
$180
Buy
41.67%
Upside
Reiterated
08/22/25
Positive Outlook for Axsome Therapeutics Amidst SYMBRAVO's Market Expansion and Patent StrengthValuation and Risks. Our Buy rating and $180 price target are based on a discounted cash flow (DCF)-based analysis. We apply a 10% discount rate to all future cash flows along with a 28.1% effective tax rate and a ~16% sales and marketing offset rate. This yields a total firm value of ~$10.8B, or a price per share of $180 given ~60.4M fully diluted shares outstanding as of mid-2026.
Mizuho Securities
$200
Buy
57.41%
Upside
Reiterated
08/21/25
Needham
$150
Buy
18.05%
Upside
Reiterated
08/11/25
TD Cowen
$190
Buy
49.54%
Upside
Reiterated
08/04/25
Bank of America Securities
$173→$176
Buy
38.52%
Upside
Reiterated
08/04/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
$191→$194
Buy
52.68%
Upside
Reiterated
10/20/25
Axsome Therapeutics: Strategic Growth and Promising Commercial Progress Drive Buy RatingWe estimate Auvelity 3Q25 revenues of $129mn in MDD. Recall Axsome completed a sales force expansion for Auvelity in 1Q25, adding 40 reps to the sales force (bringing the total to 300 representatives). Mgt. has noted that TRx growth is expected throughout the remainder of the year, given the sales force expansion. 3Q25 IQVIA scripts show 8% Q/Q growth. Based on our analysis of IQVIA TRx data, estimated IQVIA script capture ratio, Auvelity GTN and pricing, we arrive at an Auvelity 3Q25 total MDD sales estimate of $129mn, which is in-line with Visible Alpha consensus estimates.
UBS
$144→$163
Buy
28.29%
Upside
Reiterated
10/16/25
RBC Capital
―
Buy
―
Reiterated
10/08/25
Leerink Partners
―
Buy
―
Reiterated
10/07/25
B. Riley Securities
$179
Buy
40.88%
Upside
Initiated
10/01/25
William Blair
―
Buy
―
Reiterated
09/19/25
Axsome Therapeutics: Strong Growth Trajectory and Financial Outlook Justify Buy RatingWe hosted for investor calls in Europe. We discuss key takeaways from our meetings in the full note. Heading into the sNDA submission for Auvelity in Alzheimer’s disease agitation (AD-A) expected this quarter, Axsome is an emerging sustainable biotech growth story, in our view. Auvelity in major depressive disorder is annualizing more than $475 million in revenue after only 11 quarters of launch, and the company is diversifying through AXS-12 (NDA expected fourth quarter 2025).
Piper Sandler
$148
Buy
16.48%
Upside
Reiterated
09/17/25
Cantor Fitzgerald
$153
Buy
20.42%
Upside
Reiterated
09/15/25
Wells Fargo
$163
Buy
28.29%
Upside
Initiated
09/03/25
H.C. Wainwright
$180
Buy
41.67%
Upside
Reiterated
08/22/25
Positive Outlook for Axsome Therapeutics Amidst SYMBRAVO's Market Expansion and Patent StrengthValuation and Risks. Our Buy rating and $180 price target are based on a discounted cash flow (DCF)-based analysis. We apply a 10% discount rate to all future cash flows along with a 28.1% effective tax rate and a ~16% sales and marketing offset rate. This yields a total firm value of ~$10.8B, or a price per share of $180 given ~60.4M fully diluted shares outstanding as of mid-2026.
Mizuho Securities
$200
Buy
57.41%
Upside
Reiterated
08/21/25
Needham
$150
Buy
18.05%
Upside
Reiterated
08/11/25
TD Cowen
$190
Buy
49.54%
Upside
Reiterated
08/04/25
Bank of America Securities
$173→$176
Buy
38.52%
Upside
Reiterated
08/04/25
Best Analysts Covering Axsome Therapeutics
1 Month
xxx
Success Rate
19/30 ratings generated profit
Average Return
+13.73%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.33% of your transactions generating a profit, with an average return of +13.73% per trade.
3 Months
xxx
Success Rate
17/24 ratings generated profit
Average Return
+13.79%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.83% of your transactions generating a profit, with an average return of +13.79% per trade.
1 Year
Success Rate
32/33 ratings generated profit
Average Return
+47.54%
reiterated a buy rating 17 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 96.97% of your transactions generating a profit, with an average return of +47.54% per trade.
2 Years
xxx
Success Rate
33/33 ratings generated profit
Average Return
+65.45%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +65.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AXSM Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
38
41
37
25
13
Buy
20
20
20
17
13
Hold
12
12
12
7
5
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
71
74
69
49
31
Each month's total comprises the sum of three months' worth of ratings.
AXSM Financial Forecast
AXSM Stock Forecast FAQ
What is AXSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is 173.25.
What is AXSM’s upside potential, based on the analysts’ average price target?
Axsome Therapeutics Inc has 36.35% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AXSM a Buy, Sell or Hold?
Axsome Therapeutics Inc has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.
What is Axsome Therapeutics Inc’s price target?
The average price target for Axsome Therapeutics Inc is 173.25. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $148.00. The average price target represents 36.35% Increase from the current price of $127.06.
The highest analyst price target is $200.00 ,the lowest forecast is $148.00. The average price target represents 36.35% Increase from the current price of $127.06.
What do analysts say about Axsome Therapeutics Inc?
Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of AXSM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.